Leukemia

Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.

Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.

The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.

Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.

Breast cancer survivors with therapy-related leukemia were found to have personal and family histories that suggested an inherited risk for cancer.

Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.

Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.

A case study of a 15-year-old CML patient suggests that a reduced intensity conditioning regimen following hematopoietic stem cell transplantation could be a good treatment option for young CML patients. The patient went on to have two pregnancies with no neonatal complications.

PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.

An increased risk for coronary heart disease was found with increasing mean heart dose of radiation in survivors of Hodgkin lymphoma.

Results from the phase II SORAML trial indicated that adding sorafenib to standard chemotherapy for younger patients with acute myeloid leukemia was effective, but also resulted in increased toxicity.

Many chronic myeloid leukemia patients who discontinue second-line dasatinib maintain a deep molecular response, according to a new study.

The presence of the gene KIR2DL5B was found to be associated with outcomes in patients with chronic phase chronic myeloid leukemia, according to a new study.

The use of reduced-intensity conditioning HSCT as a method to maintain remission was effective in a select group of older patients with acute myeloid leukemia.

In Hodgkin lymphoma survivors, both mean heart radiation dose and cumulative dose of anthracyclines significantly predicted cardiovascular disease.

In patients with chronic myeloid leukemia (CML), a prospective, long-term study has found that hematopoietic stem cell transplantation (HSCT) and drug therapy yielded similar 10-year survival outcomes.

The combination of chemotherapy with the TKI ponatinib was an effective treatment for patients with newly diagnosed Ph-positive acute lymphoblastic leukemia.

Allogeneic HSCT may be the best treatment option in older patients with acute myeloid leukemia who obtain first complete remission after induction chemotherapy.

A new risk assessment score more accurately reflects the probability of dying from chronic myeloid leukemia than do existing scoring systems.

Treatment with intermittent imatinib is feasible among elderly CML patients who are stable responders to the drug, according to a new study.

GM-CSF was associated with lower transplantation-related and cumulative mortality among patients undergoing allogeneic hematopoietic stem cell transplantation.

The antibody-drug conjugate brentuximab vedotin is effective as a frontline therapy for Hodgkin lymphoma patients over age 60 who are unfit for chemotherapy.

Data taken from EUROCARE showed large variations in survival rates from several hematologic malignancies across European countries, with lower survival in Eastern Europe and higher survival in Northern and Central Europe.

New research showed that it appears to be feasible to treat low- and high-risk patients with acute promyelocytic leukemia with the chemotherapy-free regimen of all-trans retinoic acid and arsenic trioxide.

In this interview, researchers discuss their analysis of a specific type of acute myeloid leukemia.

Anti-diabetic drugs could help eradicate leukemic stem cells in chronic myeloid leukemia (CML) patients, according to a new study.

Nonbiological factors such as insurance and marital status and county-level income were found to independently affect the survival of younger patients with AML.

Treatment with a short course of vemurafenib was effective and rapid in patients with relapsed or refractory hairy-cell leukemia, resulting in overall response rates of over 95%.

A new laboratory study shows that inhibiting the uptake of certain dipeptides could represent a novel therapeutic approach to inhibiting chronic myeloid leukemia proliferation.

Risk for leukemia was significantly lower among children in Taiwan who were infected with the enterovirus compared with children who were not infected.